

**BEST AVAILABLE COPY**

Practitioner's Docket No. MPI98-105P1RCP2DV1M

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Raju, Jeyaseelan  
Application No.: 10/626,173 Group No.: 1652  
Filed: July 24, 2003 Examiner: Monshipouri, Maryam  
For: NOVEL CARK PROTEIN AND NUCLEIC ACID MOLECULES AND USES  
THEREFOR

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**AMENDMENT TRANSMITTAL**

1. Transmitted herewith for this application is/are:
  - a. This Amendment Transmittal which includes a request for extension of time (3 pages - in duplicate);
  - b. Amendment under 37 C.F.R. §1.111 (7 pages);
  - c. Copy of the New Application Transmittal (5 pages), copy of Statement of Biological Culture Deposit (4 pages), and copy of Post Card (1 page);
  - d. Transmittal of Supplemental Information Disclosure Statement (3 pages – in duplicate);
  - e. Supplemental Information Disclosure Statement (2 pages);
  - f. Form PTO/SB/08B (6 pages);
  - g. Copy of 54 references;
  - h. Statement of Limited Recognition under 37 C.F.R. §10.9(b) for Mario Cloutier (1 page); and
  - i. Return Postcard.

**STATUS**

2. Applicant is other than a small entity.

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

- deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**


**37 C.F.R. SECTION 1.10\***

- with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"  
Mailing Label No. \_\_\_\_\_

**TRANSMISSION**

- transmitted by facsimile to the Patent and Trademark Office.

  
\_\_\_\_\_  
Signature  
Sean Hunziker

(type or print name of person certifying)

Date: January 11, 2005

01/14/2005 FME/TEK11 00000008 501668  
10626173  
120.00 DA  
01 FC:1251

\*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**Practitioner's Docket No. MPI98-105P1RCP2DV1M**

**PETITION FOR EXTENSION OF TIME**

3. The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply. Applicant petitions for an extension of time under 37 C.F.R. 1.136 (fees: 37 C.F.R. 1.17(a)(1)-(3)) for a one month extension:

Fee: \$ 120.00

Extension fee due with this request \$120.00

If an additional extension of time is required, please consider this a petition therefor.

**FEE FOR CLAIMS**

4. The fee for claims (37 C.F.R. 1.16(b)-(d)) has been calculated as shown below:

(Col. 1)	(Col. 2)	(Col. 3)	OTHER THAN A SMALL ENTITY
Claims Remaining After Amendment	Highest No. Previously Paid For	Present Extra Rate	Addit. Fee
Total 8	Minus 12 = 0	\$50.00 =	\$0.00
Indep. 1	Minus 1 = 0	\$200.00 =	\$0.00
First Presentation of Multiple Dependent Claims	0	\$360.00 =	\$0.00
		Total Addit. Fee	\$0.00
		Total additional fee for claims required	\$0.00

**FEE PAYMENT**

5. Charge Account No. 501668 the sum of \$120.00 (which includes the \$120.00 extension fee and the \$0.00 additional fee for claims). A duplicate of this transmittal is attached.

**FEE DEFICIENCY**

6. If any additional extension and/or fee is required, charge Account No. 501668. If any additional fee for claims is required, charge Account No. 501668.

**Practitioner's Docket No. MPI98-105P1RCP2DV1M**

**7. Correspondence Address**

Direct all future correspondence to:


**Customer Number 30405**  
**OR**  
Intellectual Property Department  
**MILLENNIUM PHARMACEUTICALS, INC.**  
40 Lansdowne Street  
Cambridge, MA 02139

January 11, 2005

**MILLENNIUM PHARMACEUTICALS, INC.**

By

  
\_\_\_\_\_  
Mario Cloutier  
Limited Recognition Under 37 C.F.R. §10.9(b)  
40 Lansdowne Street  
Cambridge, MA 02139  
Telephone – (617) 577-3522  
Facsimile – (617) 551-8820



# COPY

Practitioner's Docket No. MPI98-105P1RCP2DV1M

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Raju, Jeyaseelan  
Application No.: N/A Group No.: N/A  
Filed: Herewith Examiner: N/A  
For: NOVEL CARK PROTEIN AND NUCLEIC ACID MOLECULES AND USES  
THEREFOR

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

## STATEMENT OF BIOLOGICAL CULTURE DEPOSIT

I, Jean M. Silveri hereby state:

Name of Applicant or Assignee's representative

- That the following culture(s) referred to in the specification of this application have been deposited:

Plasmid cDNA pJchr013

Strain

PTA-1530

Accession number

- That the date of the above deposit is:

- before the U.S. filing date of this application.  
 after the U.S. filing date of this application and proof that the culture(s) identified above is(are) the same culture(s) described in the application as filed is attached.

---

## CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

### MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10\*

with sufficient postage as first class mail.

as "Express Mail Post Office to Address"  
Mailing Label No.: EV312194620US

### TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

Signature

Sean Hunziker

(type or print name of person certifying)

Date: July 24, 2003

\*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**Practitioner's Docket No. MPI98-105P1RCP2DV1M**

3. That the name and address of the depository is:

American Type Culture Collection (ATCC)

Name of depository

10801 University Blvd Manassas, VA 20110

Address of depository

4. That a statement that the culture(s) deposited with the above named depository was (were) viable and was (were) capable of reproduction, if appropriate, on the date of deposit is attached. Such statement is executed by:

- a.  the depository.
- b.  the applicant.
- c.  a competent third party.

5. That, with respect to the permanence of the culture(s) deposit:

- a.  the depository is an official depository, in accordance with the Budapest Treaty for the above deposited culture(s).
- b.  the depository affords permanence of the deposit for at least 30 years or at least 5 years after the most recent storage request, whichever is longest.
- c.  evidence that permanent availability of the microorganism is assured is provided in the form of the attached copy of the contract with the above-mentioned depository with respect to the deposited culture(s).

I affirm that should the microorganism(s) mutate, become nonviable or be inadvertently destroyed, applicants will replace such microorganism(s) for at least 30 years from the date of the original deposit, or at least 5 years from the date of the most recent request for release of a sample or for the life of any patent issued on the above-mentioned application, whichever period is longer.


6. That, with respect to availability of the culture(s), I affirm that the deposit has been made under conditions of assurance of (a) ready accessibility thereto by the public if a patent is granted whereby all restrictions to the availability to the public of the culture so deposited will be irrevocably removed upon the granting of the patent (M.P.E.P. 608.01 (p)), and (b) access to the culture will be available during pendency of the patent application to one determined by the Commissioner to be entitled thereto under 37 C.F.R. section 1.14 and 35 U.S.C. section 122.

**Practitioner's Docket No. MPI98-105P1RCP2DV1M**

- Evidence of the accessibility of the culture(s) as set forth above is provided in the form of the attached copy of the contract with the above mentioned depository with respect to the deposited cultures.

24 July 2003

MILLENNIUM PHARMACEUTICALS, INC.

By 

Jean M. Silveri  
Registration No. 39,030  
15 Sidney Street  
Cambridge, MA 02139  
Telephone - 617-679-7336  
Facsimile - 617-551-8820

- Inventor  
 Assignee of complete interest  
 Person authorized to sign on behalf of assignee

MP11996-105P1.R

ATCC



10801 University Blvd, Manassas, VA 20110-2209 • Telephone: 703-365-2700 • FAX: 703-365-2745


BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF  
THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

**INTERNATIONAL FORM**

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3  
AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 10.2

To: (Name and Address of Depositor or Attorney)

Millennium Pharmaceuticals, Inc.  
Attn: Jeyaseelan Raju  
640 Memorial Drive  
Cambridge, MA 02139



Deposited on Behalf of: Millennium Pharmaceuticals, Inc.

Identification Reference by Depositor:

Patent Deposit Designation

Plasmid cDNA pJchr013 PTA-1530

The deposit was accompanied by:  a scientific description  a proposed taxonomic description indicated above.

The deposit was received March 21, 2000 by this International Depository Authority and has been accepted.

AT YOUR REQUEST:  We will inform you of requests for the strain for 30 years.

The strain will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strain, and ATCC is instructed by the United States Patent & Trademark Office or the depositor to release said strain.

If the culture should die or be destroyed during the effective term of the deposit, it shall be your responsibility to replace it with living culture of the same.

The strain will be maintained for a period of at least 30 years from date of deposit, or five years after the most recent request for a sample, whichever is longer. The United States and many other countries are signatory to the Budapest Treaty.

The viability of the culture cited above was tested March 29, 2000. On that date, the culture was viable.

International Depository Authority: American Type Culture Collection, Manassas, VA 20110-2209 USA.

Signature of person having authority to represent ATCC:

Barbara E. Coupé, Administrator, Patent Depository

Date: March 30, 2000

cc: Cynthia Kanik



Description of Paper\* and No.: New Application Transmittal (5 pages-in duplicate); 90 pages of Specification (including 87 pages of description, 2 pages of claims, and 1 page of abstract); 35 sheets of formal drawings (including Figures 1A, 1B, 2, 3A, 3B, 3C, 3D, 3E, 3F, 3G, 3H, 3I, 3J, 3K, 3L, 4A, 4B, "Sequence Listing"; 27 pages of Sequence Listing; 3 pages of Transmittal of Information Disclosure Statement; 2 pages of Information Disclosure Statement; 9 pages of copies of Form PTO-1449 (PTO/SB/08A and 08B); 1 page of Statement of Biological Culture Deposit; 1 page of ATCC Deposit Receipt; 6 pages of a copy of the executed Declaration and Power of Attorney as filed in USSN 09/947,199 filed September 5, 2001; 2 pages of a copy of the Revocation of Prior Powers of Attorney and Appointment of New Power of Attorney; 1 page of a copy of the Notice of Acceptance of Power of Attorney; a copy of the Notice of Recordation of Assignment Document, Recordal Sheet and a copy of the executed assignment to Millennium Pharmaceuticals, Inc.; and this return postcard.

COPY

Name of Applicant(s): Jeyaseelan Raju

Intf. Or Serial No.: N/A


Title: Novel Cark Protein and Nucleic Acid Molecules and Uses Therefor

Date: July 24, 2003

Attorneys: Jean M. Silveri

\*with Certificate of Express Mailing No.: EV312194620US

**First Class**



Attorney Docket No.: MPI98-105P1RCP2DV1M

THE 'RECEIVED' STAMP OF THE PATENT AND TRADEMARK OFFICE IMPRINTED  
HEREON ACKNOWLEDGES THE FILING OF:

Description of Paper\* and No.: New Application Transmittal (5 pages-in duplicate); 90 pages of Specification (including 87 pages of description, 2 pages of claims, and 1 page of abstract); 35 sheets of formal drawings (including Figures 1A, 1B, 2, 3A, 3B, 3C, 3D, 3E, 3F, 3G, 3H, 3I, 3J, 3K, 3L, 4A, 4B, "Sequence Listing"; 27 pages of Sequence Listing; 3 pages of Transmittal of Information Disclosure Statement; 2 pages of Information Disclosure Statement; 9 pages of copies of Form PTO-1449 (PTO/SB/08A and 08B); 1 page of Statement of Biological Culture Deposit; 1 page of ATCC Deposit Receipt; 6 pages of a copy of the executed Declaration and Power of Attorney as filed in USSN 09/947,199 filed September 5, 2001; 2 pages of a copy of the Revocation of Prior Powers of Attorney and Appointment of New Power of Attorney; 1 page of a copy of the Notice of Acceptance of Power of Attorney; a copy of the Notice of Recordation of Assignment Document, Recordal Sheet and a copy of the executed assignment to Millennium Pharmaceuticals, Inc.; and this return postcard.


Name of Applicant(s): Jeyaseelan Raju

Intf. Or Serial No.: N/A

Title: Novel Cark Protein and Nucleic Acid Molecules and Uses Therefor

Attorneys: Jean M. Silveri

17858 U.S. PTO  
10/626173



07/24/03

Date: July 24, 2003

\*with Certificate of Express Mailing No.: EV312194620US



# COPY

Practitioner's Docket No. : MPI98-105P1RCP2DV1M

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

### NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of  
Inventor(s): Raju, Jeyaseelan

For: NOVEL CARK PROTEIN AND NUCLEIC ACID MOLECULES AND USES THEREFOR

#### 1. Type of Application

This new application is for a(n)

- Original (nonprovisional)
- Design
- Plant
- Divisional.
- Continuation.
- Continuation-in-part (C-I-P).

---

#### CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

##### MAILING

- deposited with the United States Postal Service in an envelope addressed to the Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.  
**37 C.F.R. SECTION 1.8(a)** **37 C.F.R. SECTION 1.10\***

- with sufficient postage as first class mail.

as "Express Mail Post Office to Address"  
Mailing Label No. EV312194620US

##### TRANSMISSION

- transmitted by facsimile to the Patent and Trademark Office.

  
Signature

Sean Hunziker

(type or print name of person certifying)

Date: July 24, 2003

\*WARNING: *Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. Section 1.10(b).*

*"Since the filing of correspondence under [Section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.*

**Practitioner's Docket No. : MPI98-105P1RCP2DV1M**

**2. Benefit of Prior U.S. Application(s) (35 U.S.C. Sections 119(e), 120, or 121)**

- The new application being transmitted claims the benefit of prior U.S. Application Number 09/947,199 filed September 5, 2001 which is a CIP of U.S. Application Number 09/458,457 filed December 10, 1999, which is a CIP of U.S. Application Number 09/291,839 filed April 14, 1999 which claims priority from U.S. Application Number 60/111,938 filed December 11, 1998.

**3. Maintenance of Copendency of Prior Application**

- A.  Extension of time in prior application  
B.  Conditional Petition for Extension of Time in Prior Application

*(complete this item, if previous item not applicable)*

- A conditional petition for extension of time is being filed in the pending prior application.  
 A copy of the conditional petition filed in the prior application is attached.

**4. Abandonment of Prior Application (if applicable)**

- Please abandon the prior application at a time while the prior application is pending, or when the petition for extension of time or to revive in that application is granted, and when this application is granted a filing date, so as to make this application copending with said prior application.

**Notification in Parent Application of This Filing**

- A notification of this continuation is being filed in the parent application from which this application claims priority under 35 U.S.C. Section 120.

**5. Papers Enclosed**

**Required for Filing Date under 37 C.F.R. Section 1.53(b) (Regular) or 37 C.F.R. Section 1.153 (Design) Application**

90 Pages of Specification, including

87 Pages of Description

2 Pages of Claims

1 Page of Abstract

35 Sheet of Drawings (Figure(s) 1A, 1B, 2, 3A, 3B, 3C, 3D, 3E, 3F, 3G, 3H, 3I, 3J, 3K, 3L, 4A, 4B, 5A, 5B, 5C, 5D, 6A, 6B, 7A, 7B, 7C, 7D, 7E, 7F, 8A, 8B, 9, 10, 11 and 12

- The enclosed drawing(s) are photograph(s), and there is also attached a "PETITION TO ACCEPT PHOTOGRAPH(S) AS DRAWING(S)." 37 C.F.R. Section 1.84(b).

- Formal  
 Informal

**Practitioner's Docket No. : MPI98-105P1RCP2DV1M**

**6. Additional Papers Enclosed**

- Information Disclosure Statement (37 C.F.R. Section 1.98)
- Copies of Form PTO-1449 (PTO/SB/08A and 08B) as filed in U.S. Application No. 09/947,199 filed September 5, 2001
- Citations
- Declaration of Biological Deposit with a copy of the ATCC Deposit Receipt
- 27 pages of paper copy of Sequence Listing (37 CFR Section 1.821-1.823), and 4 pages of Submission of "Sequence Listing," Computer Readable Copy, and/or Amendment Pertaining Thereto for Biotechnology Invention Containing Nucleotide and/or Amino Acid Sequence (37 CFR Section 1.821(f))
- Authorization of Attorney(s) to Accept and Follow Instructions from Representative
- Special Comments
- Other:

**7. Declaration or Oath (including power of attorney)**

- (6 pages) A copy of the executed Combined Declaration and Power of Attorney, as filed in parent application number 09/947,199 filed September 5, 2001 is enclosed.
- (2 pages) A copy of the Revocation of Prior Powers of Attorney and Appointment of New Power of Attorney as filed in parent application number 09/947,199 filed September 5, 2001 is enclosed.
- (1 page) A copy of the Notice of Acceptance of Power of Attorney as received from the U.S. Patent Office in parent application number 09/947,199 filed September 5, 2001 is enclosed.

**8. Assignment**

- A copy of the Notice of Recordation of Assignment Document, Recordal Sheet and assignment of the invention to Millennium Pharmaceuticals, Inc. as received from the U.S. Patent Office in parent application number 09/947,199 filed September 5, 2001
  - is enclosed.
  - will follow.

Practitioner's Docket No. : MPI98-105P1RCP2DV1M

**9. Related Applications:**

Please amend the specification by replacing the Related Applications paragraph with the paragraph below:

This application claims the benefit of prior U.S. Application Number 09/947,199 filed September 5, 2001 which is a CIP of U.S. Application Number 09/458,457 filed December 10, 1999, which is a CIP of U.S. Application Number 09/291,839 filed April 14, 1999 which claims priority from U.S. Application Number 60/111,938 filed December 11, 1998.

**10. Fee Calculation (37 C.F.R. Section 1.16)**

A.  Regular application

CLAIMS AS FILED					
Claims	Number Filed	Basic Fee Allowance	Number Extra	Rate	Basic Fee 37 C.F.R. Section 1.16(a) \$750.00
Total Claims (37 C.F.R. Section 1.16(c))	12	- 20 =	0	\$18.00	\$0.00
Independent Claims (37 C.F.R. Section 1.16(b))	1	- 3 =	0	\$84.00	\$0.00
Multiple Dependent Claim(s), if any (37 C.F.R. Section 1.16(d))	0	\$280.00			\$0.00

**Filing Fee Calculation** **\$750.00**

- Amendment canceling extra claims is enclosed.
- Amendment deleting multiple-dependencies is enclosed.
- Fee for extra claims is not being paid at this time.

Practitioner's Docket No. : MPI98-105P1RCP2DV1M

**11. Method of Payment of Fees**

- Check in the amount of \$ \_\_\_\_\_.
- Charge Account No. 501668 in the amount of \$750.00  
A duplicate of this transmittal is attached.

**12. Authorization to Charge Additional Fees**

- The Commissioner is hereby authorized to charge the following additional fees by this paper and during the entire pendency of this application to Account No. 501668.
- 37 C.F.R. Section 1.16(a), (f) or (g) (filing fees)
- 37 C.F.R. Section 1.16(b), (c) and (d) (presentation of extra claims)
- 37 C.F.R. Section 1.16(e) (surcharge for filing the basic filing fee and/or declaration on a date later than the filing date of the application)
- 37 C.F.R. Section 1.17(a)(1)-(5) (extension fees pursuant to Section 1.136(a))
- 37 C.F.R. Section 1.17 (application processing fees)
- 37 C.F.R. Section 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. Section 1.311(b))

**13. Instructions as to Overpayment**

- Credit Account No. 501668.
- Refund

**14. Correspondence Address**


Direct all future correspondence to:

Customer Number 30405  
OR  
Intellectual Property Department  
MILLENNIUM PHARMACEUTICALS, INC.  
75 Sidney Street  
Cambridge, MA 02139

July 24, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By

  
Jean M. Silveri  
Registration No. 39,030  
75 Sidney Street  
Cambridge, MA 02139  
Telephone - 617-679-7336  
Facsimile - 617-551-8820

- Statement Where No Further Pages Added  
 This transmittal ends with this page.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**